YieldMax AMD Option Income Strategy ETF vs Bristol-Myers Squibb Co — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.66, while Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while YieldMax AMD Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | BMY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $65.89 |
52-Week Low | $29.80 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.
Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Trailing returns across standard periods
Latest headlines on both assets
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →